Skip to content

Clinical trials

Observational Irritable Bowel Syndrome trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Irritable Bowel Syndrome Phase: Observational Clear all

189 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20031
20041
20051
20062
20073
20087
200911
20109
201113
20128
20137
20147
20158
201611
201712
20188
20194
20206
202111
202211
202314
20248
202515
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed91
Unknown status47
Recruiting17
Not yet recruiting10
Terminated8
Enrolling by invitation6
Withdrawn4
Suspended3
Active, not recruiting3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Shandong University6
Mayo Clinic5
Assiut University4
Region Örebro County4
Sohag University4
University of California, Los Angeles4
University of Palermo4
Georgetown University3
Indiana University3
Second Affiliated Hospital of Xi'an Jiaotong University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Irritable Bowel Syndrome189
Inflammatory Bowel Diseases31
Colitis, Ulcerative24
Crohn Disease20
Fibromyalgia17
Constipation15
Celiac Disease14
Gastrointestinal Diseases13
Abdominal Pain12
Fatigue Syndrome, Chronic11

Trials

Showing 26 to 50 of 189. Each trial links to its page on Pharma Observatory.

89 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.